Source link : https://www.newshealth.biz/health-news/complement-inhibitor-shows-promise-for-rare-kidney-disorder/
SAN DIEGO — Intravenous ravulizumab (Ultomiris) yielded clinically meaningful reductions in IgA nephropathy-related proteinuria in a small, mid-stage trial. The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) compared with the 22 patients on placebo (P=0.0011), reported James Tumlin, MD, of Emory University in Atlanta, […]
Author : News Health
Publish date : 2024-10-28 19:08:58
Copyright for syndicated content belongs to the linked Source.